# FUL earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/FUL) · [Earnings tab](https://www.lopjlb.com/stock/FUL?tab=earnings) Updated: 2026-09-23T06:07:55 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly calls, HB Fuller’s outlook shifted from modest top‑line growth and early margin expansion to a landscape marked by demand volatility, aggressive pricing, and raw‑material cost pressure. Early calls (Q3‑Q4 2024) highlighted mixed demand – construction adhesives held up while end‑use and solar segments weakened – and a lowered FY 2024 EBITDA guide. By FY 2025 the company emphasized pricing discipline, modest organic growth and continued macro‑demand uncertainty, while launching new PFAS‑free products and maintaining share‑buyback momentum. The Q2 2025 call introduced a raised outlook driven by pricing and cost‑saving actions, yet warned of constrained demand and tariff exposure. In Q3‑Q4 2025 demand remained uneven, inventory buildup surfaced, and the solar business’s oversupply pressures persisted. The 2026 cycle saw a sharp revenue dip but margin expansion from a 10% price hike, a strategic exit from solar, and heightened supply‑chain risk from Middle‑East conflicts. Throughout, the firm pursued footprint optimization, debt reduction and the “Quantum Leap” restructuring, while integrating acquisitions such as ND Industries and Advanced Medical Solutions. Overall, the narrative moves from early growth optimism through a period of demand‑driven headwinds to a focus on pricing, cost control and portfolio reshaping to sustain margins amid macro‑economic and geopolitical uncertainty. ## Latest CallCard · Q2 HB Fuller posted strong Q2 revenue and earnings growth, expanded margins, and announced a strategic acquisition of Advanced Medical Solutions while reaffirming an upgraded FY2026 outlook. **Guidance:** raised — Adjusted EBITDA and EPS guidance midpoints were increased for FY2026. **Tone:** mgmt 0.7 · Q&A pressure 0.5 · divergence 0.3 Prepared remarks highlighted strong execution, pricing actions and confidence in competitive position, signaling optimism. ### Demand visibility Demand remains resilient, especially in medical, supported by structural tailwinds. Medical demand is non‑discretionary and growing ~8% annually; other segments saw mixed volume trends but pricing helped sustain revenue. ### Margins / costs Margins improving via pricing and restructuring, but raw‑material inflation remains a headwind. EBITDA margin expanded 70 bps to 19.1%; adjusted gross profit margin rose 200 bps; raw material costs are not expected to fully revert to pre‑disruption levels. ### Capital allocation Focus on disciplined allocation: deleveraging, share buybacks and the AMS acquisition. Net debt/EBITDA down to 3.1x; repurchased ~750k shares; evaluating asset sales; pursuing AMS to boost growth and margin profile. ### Milestones - **Advanced Medical Solutions acquisition** [at_risk]: All‑cash GBP 2.85 offer; closing expected end of calendar 2026 pending shareholder and regulatory approvals. - **Quantum Leap restructuring** [on_track]: Restructuring savings contributing to margin expansion and cost improvements. - **Pricing initiatives** [on_track]: Pricing actions gaining traction, offsetting raw material cost pressure. - **Supply chain continuity program** [on_track]: Global sourcing organization maintaining supply despite market disruption. - **Share repurchase program** [delivered]: Repurchased approximately 750,000 shares in Q2. - **Deleveraging plan** [on_track]: Target net debt/EBITDA 2.5‑3x within two years, down from ~4x. ### Fears / risks - **Supply chain disruption**: Risk of intermittent shortages persists as Middle East conflict effects linger. - **Raw material cost inflation**: Raw material costs unlikely to return to pre‑disruption levels, pressuring margins. - **Geopolitical risk**: Uncertainty around resolution of Middle East conflict could affect global supply chains. - **Acquisition integration risk**: Integrating AMS may present execution challenges and cost‑synergy uncertainty. - **Leverage level**: Higher leverage than peers raises concerns; deleveraging depends on cash flow and possible asset sales. - **Regulatory approval risk**: UK takeover law and other regulators must approve the AMS transaction. - **Market demand volatility**: Medical demand is stable, but other segments face volume weakness. - **Asset sale execution risk**: Divesting businesses could be complex and generate dyssynergies. ### Key quotes > “We executed very well in the second quarter, delivering strong year-on-year revenue, EBITDA, and EPS growth, with results above the midpoint of our EBITDA guidance range.” — Celeste Mastin > “Our global sourcing capabilities and swift pricing actions have enabled us to maintain supply continuity and reliably serve our customers through this market disruption.” > “Adjusted EBITDA for the quarter was $181 million, up 9% versus last year, as pricing execution and restructuring savings more than offset slightly lower volume.” > “We identified AMS as long ago as 2023 as a company that we were highly interested in.” — Celeste Mastin > “We anticipate being able to deleverage down from what will roughly be four times to our target range of 2.5 to three times within two years.” ## Quarter one-liners - **2026 Q2:** HB Fuller posted strong Q2 revenue and earnings growth, expanded margins, and announced a strategic acquisition of Advanced Medical Solutions while reaffirming an upgraded FY2026 outlook. - **2026 Q1:** HB Fuller Q1 2026 saw revenue down 6.6% YoY but margin expansion and a 10% price hike helped lift EBITDA, while Middle East supply shocks drive raw‑material risk and the company raised FY guidance. - **2025 Q4:** HB Fuller posted double‑digit EPS growth, 19% EBITDA margin and solid momentum in Q4 2025, while flagging a challenging 2026 backdrop but maintaining guidance for modest revenue growth and margin expansion. - **2025 Q3:** HB Fuller posted a solid Q3 with margin expansion and modest EBITDA growth, but warned of subdued demand, tighter guidance and temporary inventory buildup as it navigates macro headwinds. - **2025 Q2:** H.B. Fuller posted modest revenue decline but 5% EBITDA growth, raised full‑year outlook, highlighted margin expansion from pricing, cost savings and acquisitions, and flagged continued demand uncertainty and tariff risks. - **2025 Q1:** HB Fuller posted modest 1.9% organic revenue growth, reaffirmed FY2025 guidance, highlighted pricing discipline, market‑share gains in HHC and BAS, noted raw‑material cost pressure and discussed tariff and PFAS dynamics. - **2024 Q4:** Fuller reported FY2024 record EBITDA margin but warned of Q4 volume slowdown, pricing delays and raw‑material cost pressure, while outlining cost‑saving footprint cuts and recent medical‑adhesive acquisitions. - **2024 Q3:** HB Fuller posted modest top‑line growth and 6% EBITDA increase in Q3, highlighted margin expansion from volume leverage and restructuring, lowered FY2024 EBITDA guidance, completed the HS Butyl acquisition and flagged solar weakness and raw‑material pricing headwinds. ## Theme arcs - **Demand dynamics** (deteriorating): Demand moved from mixed strength to constrained, uneven and uncertain across end‑markets, with solar weakness persisting until exit. - **Margin trajectory** (improving): Margins shifted from early volume‑leverage gains to raw‑material pressure, then recovered via pricing, cost‑savings and restructuring. - **Raw‑material cost volatility** (stable): Cost inflation remained a recurring headwind, prompting pricing actions and sourcing mitigation. - **Solar segment exposure** (resolved): Solar weakness was a constant concern until the business was exited in Q1 2026. - **Acquisition integration** (new): Multiple acquisitions (HS Butyl, ND Industries, GEM, Medifill, Advanced Medical Solutions) entered the pipeline, with varying execution risk. - **Capital allocation** (stable): Share repurchases, debt reduction and footprint optimization were consistently emphasized. - **Macro‑economic slowdown** (deteriorating): Repeated references to weaker manufacturing and consumer demand heightened uncertainty. - **Tariff/geopolitical risk** (stable): Tariff exposure and geopolitical tensions were repeatedly flagged as demand dampeners. ## Fear persistence - **Macro demand slowdown** [recurring]: Repeatedly cited as limiting volume growth across calls. - **Solar market weakness** [resolved]: Initially a persistent concern, ended with business exit in 2026. - **Raw material cost volatility** [recurring]: Continuous price swings pressured margins. - **Pricing pressure** [recurring]: Pricing declines and delayed price actions noted repeatedly. - **Tariff/geopolitical risk** [recurring]: Ongoing uncertainty affecting manufacturing demand. - **Inventory buildup** [new]: Temporary inventory increase highlighted in Q3 2025. ## Guidance path 2024 Q3:lowered → 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:raised → 2025 Q3:lowered → 2025 Q4:maintained → 2026 Q1:raised → 2026 Q2:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/FUL`